Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Account Payables: 2017-2025

Historic Change in Account Payables for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $377,000.

  • Aclaris Therapeutics' Change in Account Payables fell 4.07% to $377,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 193.91%. This contributed to the annual value of -$4.2 million for FY2024, which is 184.32% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Change in Account Payables of $377,000 as of Q3 2025, which was down 84.57% from $2.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Change in Account Payables high stood at $3.2 million for Q2 2023, and its period low was -$3.5 million during Q2 2024.
  • Its 3-year average for Change in Account Payables is -$107,000, with a median of $377,000 in 2025.
  • As far as peak fluctuations go, Aclaris Therapeutics' Change in Account Payables soared by 931.44% in 2021, and later plummeted by 654.31% in 2024.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Change in Account Payables stood at $2.4 million in 2021, then grew by 13.76% to $2.7 million in 2022, then tumbled by 114.66% to -$394,000 in 2023, then tumbled by 654.31% to -$3.0 million in 2024, then fell by 4.07% to $377,000 in 2025.
  • Its Change in Account Payables stands at $377,000 for Q3 2025, versus $2.4 million for Q2 2025 and $1.7 million for Q1 2025.